These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

743 related items for PubMed ID: 16964829

  • 41. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
    Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, Moyle G, Mancini M, Percival L, Yang R, Thiry A, McGrath D, CASTLE Study Team.
    Lancet; 2008 Aug 23; 372(9639):646-55. PubMed ID: 18722869
    [Abstract] [Full Text] [Related]

  • 42. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
    Rudin C, Burri M, Shen Y, Rode R, Nadal D, Pediatric Infectious Disease Group of Switzerland, Swiss Mother and Child HIV Cohort Study (MoCHiV).
    Pediatr Infect Dis J; 2008 May 23; 27(5):431-7. PubMed ID: 18382386
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection.
    Calza L, Manfredi R, Pocaterra D, Chiodo F.
    Int J STD AIDS; 2008 Aug 23; 19(8):541-4. PubMed ID: 18663041
    [Abstract] [Full Text] [Related]

  • 45. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
    Moeremans K, Hemmett L, Hjelmgren J, Allegri G, Smets E.
    Pharmacoeconomics; 2010 Aug 23; 28 Suppl 1():147-67. PubMed ID: 21182349
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children.
    Rudin C, Wolbers M, Nadal D, Rickenbach M, Bucher HC, Pediatric Infectious Disease Group of Switzerland (PIGS), Swiss Mother and Child HIV Cohort Study (MoCHiV).
    Arch Dis Child; 2010 Jun 23; 95(6):478-81. PubMed ID: 20501542
    [Abstract] [Full Text] [Related]

  • 48. A pilot study of switch to lopinavir/ritonavir (LPV/r) monotherapy from nonnucleoside reverse transcriptase inhibitor-based therapy.
    Pierone G, Mieras J, Bulgin-Coleman D, Kantor C, Shearer J, Fontaine L, Fath M, Norton M.
    HIV Clin Trials; 2006 Jun 23; 7(5):237-45. PubMed ID: 17162317
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection.
    Haubrich RH, Riddler SA, Ribaudo H, Direnzo G, Klingman KL, Garren KW, Butcher DL, Rooney JF, Havlir DV, Mellors JW, AIDS Clinical Trials Group (ACTG) A5160 and A5142 Study Teams.
    AIDS; 2011 Nov 28; 25(18):2269-78. PubMed ID: 21941167
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study.
    Dai L, Liu A, Zhang H, Wu H, Zhang T, Su B, Shao Y, Li J, Ye J, Scott SR, Mahajan SD, Schwartz SA, Yu H, Sun L.
    Curr HIV Res; 2019 Nov 28; 17(5):324-334. PubMed ID: 31654514
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients.
    Allavena C, Ferré V, Brunet-François C, Delfraissy JF, Lafeuillade A, Valantin MA, Bentata M, Michelet C, Poizot-Martin I, Dailly E, Launay O, Raffi F, Bitherapy Kaletra-Sustiva Study Group.
    J Acquir Immune Defic Syndr; 2005 Jul 01; 39(3):300-6. PubMed ID: 15980689
    [Abstract] [Full Text] [Related]

  • 59. Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children.
    Fraaij PL, Neubert J, Bergshoeff AS, van Rossum AM, Hartwig NG, Schroten H, Korn K, Burger DM, de Groot R, Niehues T.
    Antivir Ther; 2004 Apr 01; 9(2):297-9. PubMed ID: 15134193
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 38.